Emflaza

Emflaza
製造元: Lupin

Emflazaは、満5歳以上の患者のデュシェンヌ型筋ジストロフィー(DMD)の治療のために指示されたコルチコステロイドである。

6mg

パッケージ 節約 あたり タブレット 価格 ご注文
180 タブレット ¥ 33117.38 ¥ 104.06 ¥ 18731.68
120 タブレット ¥ 20158.72 ¥ 120.06 ¥ 14407.32
90 タブレット ¥ 12958.66 ¥ 144.07 ¥ 12965.87
60 タブレット ¥ 6479.33 ¥ 180.06 ¥ 10803.69
30 タブレット ¥ 288.05 ¥ 8641.51

24mg

パッケージ 節約 あたり タブレット 価格 ご注文
120 タブレット ¥ 14385.70 ¥ 660.61 ¥ 79272.71
  • 無料航空便配送
90 タブレット ¥ 7547.81 ¥ 696.62 ¥ 62696.00
  • 無料航空便配送
60 タブレット ¥ 3592.82 ¥ 720.61 ¥ 43236.38
  • 無料航空便配送
36 タブレット ¥ 717.12 ¥ 760.57 ¥ 27380.40
  • 無料航空便配送
24 タブレット ¥ 780.49 ¥ 18731.68

30mg

パッケージ 節約 あたり タブレット 価格 ご注文
90 タブレット ¥ 14394.71 ¥ 800.73 ¥ 72065.44
  • 無料航空便配送
60 タブレット ¥ 5755.00 ¥ 864.75 ¥ 51885.10
  • 無料航空便配送
36 タブレット ¥ 1437.85 ¥ 920.73 ¥ 33146.21
  • 無料航空便配送
24 タブレット ¥ 960.67 ¥ 23056.04
  • 無料航空便配送

Deflazacort tablets

What is this medicine?

Deflazacort a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.

What should I tell my health care providers before I take this medicine?

They need to know if you have any of these conditions:

  • Hypersensitivity to deflazacort;
  • Alterations in Endocrine Function: Hypothalamic-pituitary-adrenal axis suppression, Cushing’s syndrome, and hyperglycemia;
  • Immunosuppression and Increased Risk of Infection: Increased risk of new, exacerbation, dissemination, or reactivation of latent infections, which can be severe and at times fatal;
  • Alterations in Cardiovascular/Renal Function: elevated blood pressure and sodium, and for decreased potassium level;
  • Gastrointestinal Perforation: GI disorders;
  • Behavioral and Mood Disturbances: euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis;
  • Effects on Bones: decreases in bone mineral density;
  • Serious Skin Rashes;
  • Ophthalmic Effects: May include cataracts, infections, and glaucoma;
  • Vaccination: Do not administer live or live attenuated vaccines to patients receiving immunosuppressive doses of corticosteroids.

How should I use this medicine?

The recommended once-daily dosage is approximately 0.9 mg/kg/day administered orally. Discontinue gradually when administered for more than a few day..

What may interact with this medicine?

  • Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage;
  • Avoid use of moderate or strong CYP3A4 inducers, as they may reduce efficacy.

What side effects may I notice from this medicine?

The most common adverse reactions are Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, and nasopharyngitis.